Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYRX NYSE:PBH NYSE:RCUS NASDAQ:ZNTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYRXCryoPort$14.00-1.5%$10.31$5.31▼$14.36$705.63M1.75731,575 shs450,816 shsPBHPrestige Consumer Healthcare$48.02-0.4%$55.97$42.62▼$87.12$2.27B0.4803,825 shs947,407 shsRCUSArcus Biosciences$23.48-1.7%$23.34$7.91▼$28.72$2.95B0.87969,894 shs516,535 shsZNTLZentalis Pharmaceuticals$4.06-1.9%$3.62$1.13▼$6.95$289.02M1.991.06 million shs546,934 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYRXCryoPort-1.55%+6.54%+33.08%+65.88%+128.01%PBHPrestige Consumer Healthcare-0.27%+2.85%-16.07%-31.00%-43.19%RCUSArcus Biosciences-1.44%-1.44%-12.03%+23.71%+171.87%ZNTLZentalis Pharmaceuticals-1.93%+0.25%+5.73%+67.77%+235.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYRXCryoPort$14.00-1.5%$10.31$5.31▼$14.36$705.63M1.75731,575 shs450,816 shsPBHPrestige Consumer Healthcare$48.02-0.4%$55.97$42.62▼$87.12$2.27B0.4803,825 shs947,407 shsRCUSArcus Biosciences$23.48-1.7%$23.34$7.91▼$28.72$2.95B0.87969,894 shs516,535 shsZNTLZentalis Pharmaceuticals$4.06-1.9%$3.62$1.13▼$6.95$289.02M1.991.06 million shs546,934 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYRXCryoPort-1.55%+6.54%+33.08%+65.88%+128.01%PBHPrestige Consumer Healthcare-0.27%+2.85%-16.07%-31.00%-43.19%RCUSArcus Biosciences-1.44%-1.44%-12.03%+23.71%+171.87%ZNTLZentalis Pharmaceuticals-1.93%+0.25%+5.73%+67.77%+235.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYRXCryoPort 2.89Moderate Buy$14.694.91% UpsidePBHPrestige Consumer Healthcare 2.17Hold$70.7547.33% UpsideRCUSArcus Biosciences 2.55Moderate Buy$33.8944.36% UpsideZNTLZentalis Pharmaceuticals 2.14Hold$5.8343.68% UpsideCurrent Analyst Ratings BreakdownLatest PBH, ZNTL, RCUS, and CYRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026ZNTLZentalis Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/20/2026CYRXCryoPort KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$15.00 ➝ $17.005/18/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.00 ➝ $35.005/18/2026PBHPrestige Consumer Healthcare Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/15/2026PBHPrestige Consumer Healthcare Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$86.00 ➝ $72.005/14/2026PBHPrestige Consumer Healthcare Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/14/2026PBHPrestige Consumer Healthcare OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/11/2026RCUSArcus Biosciences Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$20.00 ➝ $22.005/7/2026PBHPrestige Consumer Healthcare OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$77.00 ➝ $65.005/7/2026RCUSArcus Biosciences The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $34.005/6/2026CYRXCryoPort Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYRXCryoPort$176.18M4.00N/AN/A$8.94 per share1.57PBHPrestige Consumer Healthcare$1.09B2.09$5.21 per share9.22$39.84 per share1.21RCUSArcus Biosciences$247M11.95N/AN/A$4.17 per share5.63ZNTLZentalis Pharmaceuticals$67.43M4.29N/AN/A$2.57 per share1.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYRXCryoPort$78.30M$1.3510.37N/AN/A41.57%-7.92%-4.79%8/4/2026 (Estimated)PBHPrestige Consumer Healthcare$190.30M$3.9112.289.941.5417.48%11.54%6.16%8/6/2026 (Estimated)RCUSArcus Biosciences-$353M-$3.18N/AN/AN/A-156.36%-68.97%-35.27%8/5/2026 (Estimated)ZNTLZentalis Pharmaceuticals-$137.06M-$1.73N/AN/AN/AN/A-53.61%-40.67%8/5/2026 (Estimated)Latest PBH, ZNTL, RCUS, and CYRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q4 2026PBHPrestige Consumer Healthcare$1.39$1.23-$0.16$1.13$293.64 million$281.62 million5/12/2026Q1 2026ZNTLZentalis Pharmaceuticals-$0.49-$0.50-$0.01-$0.50N/AN/A5/5/2026Q1 2026RCUSArcus Biosciences-$0.92-$1.02-$0.10-$1.02$29.49 million$17.00 million5/4/2026Q1 2026CYRXCryoPort-$0.20-$0.23-$0.03-$0.25$44.86 million$47.80 million3/26/2026Q4 2025ZNTLZentalis Pharmaceuticals-$0.41-$0.49-$0.08-$0.49N/AN/A3/3/2026Q4 2025CYRXCryoPort-$0.19-$0.21-$0.02-$0.27$42.92 million$45.45 million2/25/2026Q4 2025RCUSArcus Biosciences-$1.11-$0.89+$0.22-$0.89$24.94 million$33.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYRXCryoPortN/AN/AN/AN/AN/APBHPrestige Consumer HealthcareN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/AZNTLZentalis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYRXCryoPortN/A2.092.00PBHPrestige Consumer Healthcare0.543.572.25RCUSArcus Biosciences0.194.044.04ZNTLZentalis PharmaceuticalsN/A6.196.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYRXCryoPort92.90%PBHPrestige Consumer Healthcare99.95%RCUSArcus Biosciences92.89%ZNTLZentalis PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCYRXCryoPort10.00%PBHPrestige Consumer Healthcare1.40%RCUSArcus Biosciences9.60%ZNTLZentalis Pharmaceuticals1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYRXCryoPort1,18650.40 million45.36 millionOptionablePBHPrestige Consumer Healthcare54047.37 million46.71 millionOptionableRCUSArcus Biosciences500125.77 million113.70 millionOptionableZNTLZentalis Pharmaceuticals16071.19 million69.83 millionOptionablePBH, ZNTL, RCUS, and CYRX HeadlinesRecent News About These CompaniesZentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum ...May 21 at 8:29 PM | finance.yahoo.comZentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026May 21 at 5:39 PM | globenewswire.comCritical Survey: Zentalis Pharmaceuticals (NASDAQ:ZNTL) vs. Cytek Biosciences (NASDAQ:CTKB)May 20 at 4:13 AM | americanbankingnews.comZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 13, 2026 | globenewswire.comZentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical ProgressMay 12, 2026 | globenewswire.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of "Hold" by BrokeragesMay 8, 2026 | marketbeat.comZentalis Pharmaceuticals (ZNTL) to Release Earnings on WednesdayMay 6, 2026 | marketbeat.comZentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian CancerMay 5, 2026 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comShort Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Grows By 22.2%April 30, 2026 | marketbeat.comZentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian CancerApril 21, 2026 | globenewswire.comZentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the TargetApril 20, 2026 | finance.yahoo.comZentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at ...April 18, 2026 | finance.yahoo.comZentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026April 17, 2026 | globenewswire.comA Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection MilestoneApril 13, 2026 | finance.yahoo.comWhat's behind the surge in Zentalis stock?April 10, 2026 | msn.comWhat's Behind The Surge In Zentalis Stock?April 10, 2026 | benzinga.comZentalis Pharmaceuticals (ZNTL) price target increased by 19.05% to 5.83April 10, 2026 | msn.comZentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian CancerApril 9, 2026 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2026 | globenewswire.comZentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational UpdatesMarch 26, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePBH, ZNTL, RCUS, and CYRX Company DescriptionsCryoPort NASDAQ:CYRX$14.00 -0.22 (-1.55%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$13.96 -0.04 (-0.31%) As of 05/22/2026 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.Prestige Consumer Healthcare NYSE:PBH$48.02 -0.21 (-0.44%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$47.95 -0.07 (-0.14%) As of 05/22/2026 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.Arcus Biosciences NYSE:RCUS$23.48 -0.39 (-1.65%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$23.44 -0.04 (-0.17%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Zentalis Pharmaceuticals NASDAQ:ZNTL$4.06 -0.08 (-1.93%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.00 -0.06 (-1.38%) As of 05/22/2026 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
